Entecavir: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) m (Changed protection level for "Entecavir" ([Edit=Allow only autoconfirmed users] (expires 15:56, 14 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 15:56, 14 January 2014 (UTC)))) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{XXXXX}} | |||
{{CMG}} | |||
==Overview== | |||
'''Entecavir''' ([[International Nonproprietary Name|INN]]) ({{pronEng|ɛnˈtɛkəvɪr}}) is an oral [[antiviral drug]] used in the treatment of [[hepatitis B]] infection. It is marketed under the trade name '''Baraclude''' ([[Bristol-Myers Squibb|BMS]]). | '''Entecavir''' ([[International Nonproprietary Name|INN]]) ({{pronEng|ɛnˈtɛkəvɪr}}) is an oral [[antiviral drug]] used in the treatment of [[hepatitis B]] infection. It is marketed under the trade name '''Baraclude''' ([[Bristol-Myers Squibb|BMS]]). | ||
Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B ([[lamivudine]] and [[adefovir]]). It was approved by the U.S. [[Food and Drug Administration]] (FDA) in March 2005. | Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B ([[lamivudine]] and [[adefovir]]). It was approved by the U.S. [[Food and Drug Administration]] (FDA) in March 2005. | ||
== | ==Category== | ||
Antiviral | |||
==US Brand Names== | |||
BARACLUDE<sup>®</sup> | |||
==FDA Package Insert== | |||
''' [[XXXXX description|Description]]''' | |||
'''| [[XXXXX clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[XXXXX microbiology|Microbiology]]''' | |||
'''| [[XXXXX indications and usage|Indications and Usage]]''' | |||
'''| [[XXXXX contraindications|Contraindications]]''' | |||
'''| [[XXXXX warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[XXXXX adverse reactions|Adverse Reactions]]''' | |||
'''| [[XXXXX drug interactions|Drug Interactions]]''' | |||
'''| [[XXXXX overdosage|Overdosage]]''' | |||
'''| [[XXXXX clinical studies|Clinical Studies]]''' | |||
'''| [[XXXXX dosage and administration|Dosage and Administration]]''' | |||
'''| [[XXXXX how supplied|How Supplied]]''' | |||
'''| [[XXXXX labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
==References== | |||
{{ | {{Reflist|2}} | ||
[[ | [[Category:Antibiotics]] | ||
[[Category:Wikinfect]] | |||
Revision as of 16:30, 3 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Entecavir (INN) (Template:PronEng) is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
Category
Antiviral
US Brand Names
BARACLUDE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages